GleamWall
中文EN

FULC Fulcrum Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680581 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY2,752.0%
TTM net income YoY90.0%
TTM EPS YoY89.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-27.4%
Net margin-12.2%
FCF margin-3.1%
EBITDA margin-25.3%

Returns

ROE-4.1%
ROA-3.8%
ROIC (approx.)-8.8%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets6.8%
Debt / equity0.00x
Current ratio22.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.23x
Accruals ratio-2.9%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$80.00M
R&D expense$56.10M$63.39M
SG&A expense$28.67M$36.45M
Operating income-$84.77M-$21.90M
Income tax$0$0
Net income-$74.88M-$9.72M
EBITDA-$83.38M-$20.30M
EPS (basic)-1.18-0.16
EPS (diluted)-1.18-0.16
Weighted avg. shares (diluted)63,35561,984
Balance sheet
Cash & equivalents$197.53M$58.21M
Current assets$357.48M$249.92M
PP&E, net$2.82M$3.90M
Total assets$366.28M$260.72M
Current liabilities$13.05M$11.04M
Total liabilities$17.28M$17.68M
Shareholders' equity$349.00M$243.03M
Shares outstanding66.58M53.97M
Cash flow statement
Operating cash flow-$60.06M-$2.22M
Capital expenditure$314,000$278,000
Free cash flow-$60.38M-$2.50M
Investing cash flow$30.72M$32.23M
Financing cash flow$168.67M$2.75M
Depreciation & amortization$1.39M$1.59M
Stock-based compensation$12.47M$14.55M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.